On January 7, 2021 OncoDNA, a theranostic and genomic company specializing in precision oncology, reported that it has signed a subcontract service agreement with HalioDx’s U.S.-based CLIA-certified laboratory located in Richmond, Virginia (Press release, OncoDNA, JAN 7, 2021, View Source [SID1234573656]). This agreement will enable OncoDNA to expand its unique offering of services to biopharmaceutical companies and research institutions in North America.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
OncoDNA has a proven track record in supporting the development of personalized cancer therapies. Its portfolio includes a series of comprehensive molecular diagnostic tests on both solid and liquid biopsies. Combined with an advanced bioinformatic technology, OncoDNA’s diagnostic tests offer a unique solution to the US biopharmaceutical industry.
Today, OncoDNA products and services are already used in pan-European clinical trials and research projects, such as Kura Oncology’s HRAS tipifarnib clinical study and the AURORA metastatic breast cancer research program. OncoDNA currently offers its solutions in 50 countries worldwide and has experienced an outstanding sales growth of 180% over the last 4 years. Obtaining access to HalioDx’s laboratory capabilities will further propel the global adoption of OncoDNA’s solutions in North America.
"We have found in HalioDx a trusted partner to run our diagnostic tests for research use in the U.S. We are confident that HalioDx, and most particularly its CLIA-certified laboratory in Richmond, Virginia, has the capability to perform our complex molecular profiling assays, enabling us to assist with the identification and development of future personalized cancer treatments for patients", said Jean-Pol Detiffe, Founder of OncoDNA.
Vincent Fert, HalioDx CEO commented: "We are thrilled for the opportunity to partner with OncoDNA and help them to introduce their unique precision oncology solutions to US customers. Our respective capabilities are highly complementary to foster success in this marketplace."
HalioDx is an immuno-oncology diagnostic company that operates in compliance with the Clinical Laboratory Improvement Amendments of 1988 (CLIA). Headquartered in France, the company also has CLIA-certified laboratories and compliant facilities in Richmond, US, which will help OncoDNA penetrate the North American market.